About Tekla Capital Management
Tekla Capital Management, formerly Hambrecht & Quist Capital Management (HQCM), is a Boston, MA based healthcare-focused investment manager with approximately $2.3 billion of assets under management as of September 30, 2014. Tekla serves as investment adviser to three closed-end funds: Tekla Healthcare Investors, Tekla Life Sciences Investors and Tekla Healthcare Opportunities Fund.Tekla Healthcare Investors is a diversified closed-end healthcare fund that primarily invests in the healthcare industry (including biotechnology, medical devices, and pharmaceuticals). The Fund's objective is to provide long-term capital appreciation through investments in companies in the healthcare industry believed to have significant potential for above-average long-term growth. Selection will emphasize the smaller, emerging companies with a maximum of 40% of the Fund's assets in restricted securities of both public and private companies.Tekla Life Sciences Investors is a diversified closed-end healthcare fund that invests in the life sciences (including biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies), agriculture and environmental management industries. The Fund's objective is to provide long-term capital appreciation through investments in companies in the life sciences industry believed to have significant potential for above-average long-term growth. Selection will emphasize the smaller, emerging companies with a maximum of 40% of the Fund's assets in restricted securities of both public and private companies.Tekla Healthcare Opportunities Fund (THQ) is a non-diversified closed-end fund that invests primarily in the healthcare industry. The Fund's objective is to seek current income and long-term capital appreciation through investment companies engaged in the healthcare industry, including equity securities, debt securities and pooled investment vehicles.
Tekla Capital Management Headquarter Location
2 Liberty Square 9th Floor
Boston, Massachusetts, 02109,
Latest Tekla Capital Management News
May 21, 2020
本文共1940个字，阅读需5分钟 Financing Accelerates Development of First-in-Class Therapies with Genetically Validated Mechanisms for Treatment of Autoimmune Diseases, Rare Diseases and Cancer HotSpot Therapeutics, Inc, a biotechnology company pioneering the discovery and development of first-in-class allosteric therapies targeting nature's regulatory sites, today announced the completion of a $65 million Series B financing. The financing round was led by S.R. One, Limited and included funds managed by Tekla Capital Management, MRL Ventures Fund, Solasta Ventures and Brace Pharma (via affiliate Cleva Pharma), along with co-founding investors Atlas Venture and Sofinnova Partners. Concurrent with the financing, Jill Carroll, Partner at S.R. One, Limited, and Henry Skinner, PhD, Senior Vice President, Venture at Tekla Capital Management have joined the HotSpot Board of Directors. "We are thrilled to have the support of a top tier investor syndicate to realize our vision of designing and developing first-in-class allosteric medicines," said Jonathan Montagu, CEO and co-founder of HotSpot Therapeutics. "We have proven that uncovering and targeting natural regulatory sites on proteins leads to highly differentiated molecules across a number of important target families, including kinases, transcription factors and E3 ligases. Today's financing will allow us to demonstrate the value of these molecules in patients. "HotSpot Therapeutics is creating a new paradigm for allosteric medicines that exploits natural control mechanisms. Leveraging a deep understanding of protein structure-function, the SpotFinder™ platform identifies critical regulatory regions on proteins – "regulatory hotspots" – that are amenable to small molecule drug discovery. This allows HotSpot to design first-in-class allosteric medicines with superior pharmacology, selectivity and drug-like properties.The Series B financing will support the advancement of HotSpot's lead programs to the clinic, including protein kinase C (PKC-theta) antagonists for Th2 and T-reg driven autoimmune disease and S6 kinase (S6K) antagonists for rare metabolic disease. The financing will also accelerate the discovery-stage pipeline targeting genetically validated transcription factors and E3 ligases, including CBL-B. "It is with pleasure that we welcome Jill Carroll and Henry Skinner to the HotSpot Board, both with significant experience guiding early stage companies in the transition from drug discovery into clinical development," said Bruce Booth, DPhil, Chair of HotSpot's Board of Directors and Partner at Atlas Venture. "Leveraging its proprietary SpotFinder™ technology platform, HotSpot is succeeding in critically important areas of biology that were otherwise considered intractable and undruggable," said Jill Carroll, S.R. One, Limited. "We are very excited to partner with this seasoned team to transform HotSpot into a clinical stage company and to bring first-in-class allosteric drugs targeting natural regulatory mechanisms to patients. "Regulatory hotspots are privileged sites on proteins that are often difficult to identify but possess certain common features that can be uncovered through mining of expertly curated structure, sequence and function datasets. HotSpot's SpotFinder™ platform uses advanced machine learning techniques to discover the underlying fingerprints of regulatory pockets. Using 3D structure insights from the uncovered pockets, the company has designed in-house DNA-encoded libraries (DEL) that comprise millions of exquisitely tailored molecules. A proprietary screening paradigm using custom protein constructs, phenotypic screens and biophysics assays is then used to demonstrate the differentiated properties of hotspot-targeted molecules.About HotSpot TherapeuticsHotSpot Therapeutics is targeting nature's regulatory mechanisms to create allosteric medicines that exhibit high precision and potency. The company leverages its proprietary SpotFinder™ technology, the first and only platform designed to identify and target "regulatory hotspots," a unique family of pockets that sit remote from the active site on a protein and are used by nature to control protein function. Using bespoke chemistry approaches, HotSpot is developing a pipeline of first-in-class small molecules for the treatment of autoimmune and rare diseases as well as cancer. The company has identified regulatory hotspots across multiple target classes including kinases, transcription factors and E3 ligases. HotSpot's lead compounds include the first and only allosteric inhibitors to target PKC-theta for autoimmune diseases and S6 kinase, a critical signaling node involved in the regulation of mitochondrial and metabolic function. To learn more, visit www.hotspotthera.com.multimedia:http://www.prnewswire.com/news-releases/hotspot-therapeutics-completes-65-million-series-b-financing-to-advance-pipeline-of-novel-allosteric-medicines-301063076.html 融资加速发展具有遗传验证机制的一流治疗方案，用于治疗自身免疫性疾病、罕见疾病和癌症HotSpot Therapeutics , Inc .是一家生物技术公司，致力于发现和开发针对自然监管场所的一流异体疗法，今天宣布完成6500万美元的 B 系列融资。这轮融资由 S.R.One , Limited 牵头，包括 Tekla Capital Management 、 MRL Ventures Fund 、 Solasta Ventures 和 Brace Pharma （通过关联公司 Cleva Pharma ）管理的基金，以及联合创始投资者 Atlas Venture 和 Sofinnova Partners 。在融资的同时， S.R.One , Limited 合伙人 Jill Carroll 和 Tekla Capital Management 风险投资高级副总裁 Henry Skinner 博士也加入了热点董事会。HotSpot Therapeutics 首席执行官兼联合创始人 JonathanMontagu 表示：“我们很高兴得到顶级投资者财团的支持，以实现我们设计和开发一流变构药物的愿景。”“我们已经证明，在蛋白质上发现和定位天然的调节位点会导致许多重要的目标家族的高度分化的分子，包括激酶、转录因子和 E3韧带。今天的融资将使我们能够证明这些分子在病人中的价值。”HotSpot Therapeutics 正在为利用自然控制机制的变构药物创建一个新的范例。 SpotFinder ™平台利用对蛋白质结构功能的深入了解，确定了蛋白质上的关键监管区域——“监管热点”，这些区域适合小分子药物的发现。这使得 HotSpot 能够设计出具有优良药理、选择性和类药特性的一流异体药物。B 系列融资将支持 HotSpot 向临床的先导计划的推进，包括针对 Th2和 T-reg 驱动的自身免疫性疾病的蛋白激酶 C （ PKC-theta ）拮抗剂和针对罕见代谢性疾病的 S6激酶（ S6K ）拮抗剂。这笔资金还将加速以基因验证转录因子和 E3连接酶为目标的发现阶段管道，包括 CBL-B 。“我们很高兴欢迎 Jill Carroll 和 Henry Skinner 加入 HotSpot 董事会，这两家公司都具有指导早期阶段公司从药物发现过渡到临床开发的重要经验，” HotSpot 董事会主席兼 Atlas Venture 合伙人 Bruce Booth 说。“利用其专有的 SpotFinder ™技术平台， HotSpot 在生物学中非常重要的领域取得了成功，这些领域原本被认为是难以解决和难以解决的，” Jill Carroll , S.R.One , Limited 说。“我们非常高兴与这个经验丰富的团队合作，将 HotSpot 转变为临床阶段的公司，并将针对患者的天然调节机制的一流异体药物引入临床阶段。”调控热点是蛋白质上的特权位点，这些蛋白质往往难以识别，但具有某些共同的特征，可以通过挖掘专门的结构，序列和功能数据集来发现。HotSpot 的 SpotFinder ™平台使用先进的机器学习技术来发现监管口袋的底层指纹。该公司利用从被发现的口袋里获得的三维结构洞察，设计了内部 DNA 编码库（ DEL ），其中包含数百万精心定制的分子。然后利用自定义蛋白结构、表型筛选和生物物理检测的专利筛选范例来证明热点靶分子的区别特性。关于热点疗法HotSpot Therapeutics 针对自然的调节机制，创造出高精度和效力的异体药物。该公司利用其专有的 SpotFinder ™技术，这是第一个也是唯一一个旨在识别和瞄准“监管热点”的平台。监管热点是一种独特的口袋家族，位于蛋白质活性位点的远程，自然用于控制蛋白质功能。HotSpot 采用定制的化学方法，正在开发一系列一流的小分子药物，用于治疗自身免疫性和罕见疾病以及癌症。该公司已经确定了包括激酶、转录因子和 E3连接酶在内的多个目标类的调控热点。HotSpot 的先导化合物包括第一个也是唯一一个针对自身免疫性疾病 PKC-theta 的变构抑制剂和参与调节线粒体和代谢功能的关键信号传导节点 S6激酶。要了解更多信息，请访问 www.hotspotahera.com 。多媒体： http://www.prnewswire.com/news-releases/hotspot-therapeutics-complete-65-百万系列- b-finance-to-advanced-tube-of-new-alliantic-medicines-301063076。html 以上中文文本为机器翻译，存在不同程度偏差和错误；偶尔因源网页结构局限，内容无法一次完整呈现。请理解并参考原站原文阅读。
Tekla Capital Management Team
3 Team Members
Tekla Capital Management has 3 team members, including current Chief Executive Officer, Daniel R Omstead.